Multicenter Clinical Trial Evaluating the Immunological Response of Vaccination Against Infection by Human Papillomavirus (HPV) 6, 11, 16, 18 in Girls Receiving Immunosuppressive Therapy.

Trial Profile

Multicenter Clinical Trial Evaluating the Immunological Response of Vaccination Against Infection by Human Papillomavirus (HPV) 6, 11, 16, 18 in Girls Receiving Immunosuppressive Therapy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; Corticosteroids; Immunosuppressants
  • Indications Cervical cancer; Cervical dysplasia; Genital warts; Human papillomavirus infections; Vulvar dysplasia
  • Focus Therapeutic Use
  • Acronyms PRIMAVERA
  • Most Recent Events

    • 30 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 12 Dec 2013 Planned end date changed from 1 Aug 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.
    • 12 Dec 2013 Planned number of patients changed from 35 to 37 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top